New book by Larry Connors Click here Improve your trading - See how
FinancialBusinessNews is an affiliate of Stock Profiler.US, LLC. Stock Profiler's website has been upgraded with FREE Investor Tools, Live Chats, and much more! Sign up now at www.stockprofiler.us. Companies who want to broadcast their message are encouraged to contact us at (603) 424-4420.
-------------------------------------------
Infinity Medical Group Inc. (PINKSHEETS: IMGR | Quote | Chart | News | PowerRating) closed at $0.15 Tuesday, trading 6,705 shares.
Company News- July 16, 2008: Infinity Medical Group Inc. Announces Distribution of N.V. Perricone M.D. Cosmeceuticals
Infinity Medical Group Inc. (PINKSHEETS: IMGR), a specialty healthcare development company focusing on the building, finance and management of cosmetic medical laser and dental implant clinics that offer elective medical and dental procedures, is pleased to have announced earlier today that through its partner Rejuvena Medspa, Rejuvena Skin and Laser Centre is proud to be a Canadian distributor for N.V. Perricone M.D. Cosmeceuticals. 2,000 Americans will turn 50 every day (1 every 8 seconds) for the next 20 years. Studies show the number of Americans over 55 will grow by 60% in the next 20 years and their buying power will exceed $2 trillion by 2007.
Americans spent just under $9.4 billion on cosmetic medical procedures in 2003. In 2004, American consumers spent $44.6 billion on anti-aging products and services, and the total anti-aging market is projected to reach $72 billion by 2009. (Business Communications Co. Inc. February 2005) Infinity Medical Group Inc. is a specialty healthcare development company whose primary focus is in servicing the cosmetic medical laser and dental implant fields. Infinity Medical Group provides turnkey support for both medical and dental professionals and aids in their professional development through the emerging fields of cosmetic medical lasers and dental implants. Infinity differentiates itself by offering "a hands-on approach to finance, building, systemization, branding, containment, training and development of its group of clinics." "We are excited to announce that the entire N.V. Perricone line is available directly through Rejuvena. Dr. Perricone is the focus of a series of award-wining television specials airing in the U.S. on PBS TV. He is a popular guest on American television, appearing on the Today Show, Oprah, Larry King, 20/20, Good Morning America, The View, CNN, Fox, Extra, Access Hollywood as well as many other news and lifestyle broadcasts. He has been featured in the New York Times, Wall Street Journal, Vogue, Harper's Bazaar, W, Forbes, People, WWD, USA Today and a host of other major magazines and newspapers around the globe. Vogue named Dr. Perricone one of the best dermatologists in the U.S. in 2001 -- and the opening of the Perricone Flagship store on Madison Avenue (NYC) was named one of the 'Top Ten Beauty Stories' by WWD in 2005," said Stefan Kim, CEO, Infinity Medical Group.
About Infinity Medical Group Inc.:
Infinity Medical Group Inc. is a specialty healthcare development company focusing on the building, finance and management of cosmetic medical laser and dental implant clinics offering elective procedures.
-------------------------------------------
Delcath Systems, Inc. (NASDAQ: DCTH | Quote | Chart | News | PowerRating) closed at $2.01 Tuesday, trading 24,300 shares.
Company News- July 15, 2008: Delcath Systems' Targeted Drug Delivery System for Liver Cancer Treatment to Be Featured on FOX Business News
Delcath Systems, Inc. (NASDAQ: DCTH | Quote | Chart | News | PowerRating) yesterday that CEO Richard L. Taney will appear on FOX Business Network (FBN) to discuss the Company's proprietary Percutaneous Hepatic Perfusion (PHP) System, which is designed to deliver targeted high doses of therapeutic and chemotherapeutic agents. The PHP System is currently being tested in Phase III and II clinical trials for the treatment of hepatocellular carcinoma and metastatic tumors in the liver. Also appearing on this segment will be Dr. James Pingpank of the National Cancer Institute in Bethesda, Maryland. Dr. Pingpank is the Principal Investigator for the Company's ongoing pivotal Phase III trial of metastatic melanoma in the liver. Mr. Taney will discuss the health industry's efforts towards treating cancer on a regionalized basis and provide an update on current approaches to the treatment of liver cancer, including Delcath's PHP System. Mr. Taney will be featured on the "Money for Breakfast" segment on Wednesday, July 16, 2008 to be broadcast at 7:30 AM/ET.
In making this announcement, Mr. Taney commented, "The appearance on FOX Business News is an important step in our ongoing effort to increase public awareness of the Company's targeted drug delivery system for the treatment of liver cancers. We are pleased to have the opportunity to present our technology and the promise that it holds for patients suffering from this terrible disease." FOX Business Network (FBN) is a financial news channel delivering real-time information across all platforms that impact both Main Street and Wall Street. FBN is headquartered in New York, the business capital of the world. Launched in October 2007, the Network is available in more than 35 million homes in major markets across the United States. Owned by News Corp., the Network has bureaus in Chicago, Los Angeles, Silicon Valley, Washington, DC and London. (www.foxbusiness.com).
About Delcath Systems, Inc.
Delcath Systems is a technology-based therapeutic company specializing in cancer treatment. The Company is working to complete its first Phase III clinical trial for its Percutaneous Hepatic Perfusion System ("PHP") for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The PHP System is currently being tested in Phase III and Phase II clinical trials for the treatment of hepatocellular carcinoma and metastatic tumors in the liver, including melanomas, neuroendocrine tumors and adenocarcinomas. The Company's intellectual property portfolio currently consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.
-------------------------------------------
DOR BioPharma, Inc. (OTCBB: DORB | Quote | Chart | News | PowerRating) closed at $0.137 Tuesday, trading 16,200 shares.
Company News- July 15, 2008: DOR BioPharma Enters Into Collaborative Agreement With IDIS for Named Patient Access of orBec in Europe
DOR BioPharma, Inc. (OTCBB: DORB | Quote | Chart | News | PowerRating) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments, serious gastrointestinal diseases and vaccines against certain bioterrorism agents, announced yesterday that it has executed a definitive collaborative agreement with IDIS Limited ("IDIS"), for the supply and distribution within the European Union of the Company's investigational drug orBec (oral beclomethasone dipropionate) for the treatment of gastrointestinal Graft-versus-Host disease ("GI GVHD") via a named patient program ("NPP").
IDIS is the leading specialist in the management of NPPs in Europe. An NPP is a compassionate use drug supply program under which medical practitioners can legally supply investigational drugs to qualifying patients. Under an NPP, investigational drugs can be administered to patients who are suffering from serious illnesses until the drug is approved by the European Medicines Evaluation Agency ("EMEA") or a national health authority. The NPP will allow DOR to provide a treatment option to patients with GI GVHD, an unmet medical need. The GI GVHD market in Europe is believed to be about 60% of the more than 10,000 allogeneic bone marrow/stem cell transplantations occurring there annually.
"We are very pleased to partner with IDIS to make orBec available to GI GVHD patients in Europe," stated Christopher J. Schaber, PhD, President and CEO of DOR BioPharma. "We remain steadfast in our mission to deliver orBec to patients who desperately need a therapeutic option. Based on its reach and focus, IDIS is clearly the optimal choice as a partner for implementing the NPP in Europe. We anticipate initiating this program soon knowing there is potential to generate revenues that will help to support the confirmatory orBec Phase 3 clinical trial. We have already received inquiries from clinicians in Europe interested in the availability of orBec for their patients." "We are delighted to be working with DOR to provide patients with GI GVHD access to orBec , so they can benefit from DOR's innovative therapy," said John Lagus, Vice President of Business Development for IDIS. "IDIS will work in close partnership with DOR to manage NPP requests in a way that is reliable and responsible while ensuring that all the regulatory obligations are met."
About IDIS
IDIS is the world leader in the development and implementation of Named Patient Programs and has a proven track record of working in strategic partnership with US-based companies to bring new medicines to Europe for the first time. IDIS supports its customers in over 100 countries worldwide, supplying more than 400 different medicines per month and responding to more than half a million requests on a named-patient basis to medical professionals worldwide. Headquartered near central London, IDIS has been a strategic partner to more than 40 pharmaceutical and biotech companies. For more information on IDIS, please visit the website www.idispharma.com.
About DOR BioPharma, Inc.
DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of bone marrow transplantation. DOR filed a New Drug Application for orBec with the FDA for the treatment of acute GI GVHD and received a not approvable letter in which the FDA has requested data from a confirmatory Phase 3 clinical trial to demonstrate the safety and efficacy of orBec . orBec is currently the subject of an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Oral BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. DOR has initiated a development program with its Lipid Polymer Micelle (LPM) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.
Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax, has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers.
For further information regarding DOR BioPharma, Inc., please visit the Company's website located at www.dorbiopharma.com.
-------------------------------------------
Biophan Technologies, Inc. (OTCBB: BIPH | Quote | Chart | News | PowerRating) closed at $0.0159 Tuesday, trading 430,763 shares.
Company News- July 15, 2008: Biophan Reports First Quarter 2008 Results
Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, announced yesterday the results of their operations for the first quarter ended May 30, 2008.
During the quarter ended May 30, 2008, the Company continued its commitment to invest in the Myotech Circulatory Support System (CSS) and entered into the next stage of development, with a sharpened focus on the acute resuscitation market segment, where there is a large patient population not adequately served by existing technologies. In addition, Myotech secured a Memorandum of Understanding with PPA Technologies in Germany, a potential strategic partner for the development of the Myotech Circulatory Support System, which Biophan expects to be approved for sale in the US, in 24-30 months.
Biophan also expanded its intellectual property through the acquisition of the patent portfolio from Nanoset, LLC, which provides broad coverage on novel medical uses of nanomagnetic materials. And, the Company saw the issuance of two new patents expanding coverage of the biothermal power supply and providing coverage for an optical MRI catheter system, which is a continuation of its core strategy of pursuing grants and strategic partnerships for the development of its earlier stage technologies.
The Company ended the quarter with $5.7 million in cash, and recognized revenue from license fees and testing and consulting services of $0.22 million.
About Biophan Technologies, Inc.
Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company is helping to commercialize the Myotech Circulatory Support System, which has significant potential to improve the treatment of acute heart failure. Biophan Technologies, Inc. holds a 70% interest in Myotech with rights to acquire additional equity, and is leading Myotech's business development efforts. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.
-------------------------------------------
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. FinancialBusinessNews.US has not been compensated for services rendered; FinancialBusinessNews.US is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers, go to http://www.financialbusinessnews.us/ (disclaimers).
CONTACT: FinancialBusinessNews.US e-mail: info@http://www.financialbusinessnews.us WWW: http://www.financialbusinessnews.us/
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
